ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) and BioWa, Inc. (BioWa) today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. Under the agreement Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT® Technology.
"We are delighted to have access to BioWa's POTELLIGENT® Technology which combined with our therapeutic antibodies could make these enhanced antibodies more valuable assets for partnering" said Manish Singh, CEO of IMUC.
"We are excited to expand our set of small company arrangements with IMUC. In large part, our decision to partner with IMUC was driven by our interest in novel therapeutic antibody targets in oncology that possess strong preclinical documentation. " said Yasunori Yamaguchi, President and CEO of BioWa.
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes